NEW YORK (GenomeWeb) – Transplant Genomics (TGI) and Quark Pharmaceuticals announced today that they have signed a deal to use Transplant's TruGraf post-kidney transplant blood test to evaluate patients in a Phase III trial of Quark's RNAi-based treatment for delayed graft function (DGF).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Sep
26
Sponsored by
PerkinElmer

This webinar will describe a protocol and proof-of-principle experiments for Cellular Indexing of Transcriptome and Epitopes by Sequencing (CITE-seq).